Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

IXICO PLC

Healthcare GB IXI

8.65GBX
0.00(0%)

Last update at 2026-06-05T14:28:00Z

Day Range

8.318.85
LowHigh

52 Week Range

7.0015.00
LowHigh

Fundamentals

  • Previous Close 8.65
  • Market Cap6.83M
  • Volume180619
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.40200M
  • Revenue TTM6.53M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM 3.18M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -2.44900M -2.09400M -1.36100M 0.89M 1.16M
Minority interest - - - - -
Net income -1.65100M -2.00100M -1.17800M 1.03M 1.57M
Selling general administrative 2.49M 2.91M 2.85M 2.25M 2.44M
Selling and marketing expenses 1.67M 1.40M 1.32M 1.23M 1.15M
Gross profit 2.91M 2.71M 3.27M 5.24M 6.02M
Reconciled depreciation 0.41M 0.47M 0.62M 0.64M 0.61M
Ebit -2.43300M -2.15400M -1.33200M 0.91M 1.18M
Ebitda -2.02200M -1.94500M -0.70700M 1.56M 1.74M
Depreciation and amortization 0.41M 0.21M 0.62M 0.65M 0.56M
Non operating income net other - - - - -
Operating income -2.53100M -2.15400M -1.43700M 0.91M 1.18M
Other operating expenses 9.09M 7.92M 8.10M 7.88M 8.03M
Interest expense 0.02M 0.03M 0.03M 0.03M 0.02M
Tax provision -0.79800M -0.09300M -0.18300M -0.14700M -0.41500M
Interest income 0.12M 0.09M 0.10M 0.01000M 0.00100M
Net interest income 0.10M 0.06M 0.08M -0.02300M -0.02100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.79800M -0.09300M -0.18300M -0.14700M -0.41500M
Total revenue 6.53M 5.77M 6.67M 8.64M 9.19M
Total operating expenses 5.44M 4.87M 4.71M 4.48M 4.87M
Cost of revenue 3.63M 3.06M 3.40M 3.40M 3.17M
Total other income expense net 0.08M 0.06M 0.08M -0.02300M -0.02100M
Discontinued operations - - - - -
Net income from continuing ops -1.65100M -2.00100M -1.17800M 1.03M 1.57M
Net income applicable to common shares - - - 1.03M 1.57M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 13.84M 11.19M 12.99M 14.65M 14.15M
Intangible assets 7.18M 6.37M 6.15M 4.59M 2.71M
Earning assets - - - - -
Other current assets - 0.49M - 3.48M 3.67M
Total liab 2.10M 1.72M 1.56M 2.16M 2.93M
Total stockholder equity 11.74M 9.46M 11.43M 12.49M 11.22M
Deferred long term liab - - - - -
Other current liab 1.74M 0.98M 1.08M 1.36M 1.48M
Common stock 0.93M 0.48M 0.48M 0.48M 0.48M
Capital stock 0.93M 0.48M 0.48M 0.48M 0.48M
Retained earnings -84.60500M 7.46M -7.36000M -6.23400M -7.60300M
Other liab - - - 0.03M 0.11M
Good will - - - - -
Other assets - - - - -
Cash 3.54M 1.79M 4.03M 5.77M 6.68M
Cash and equivalents - - - - -
Total current liabilities 2.06M 1.57M 1.28M 1.74M 2.29M
Current deferred revenue - - - - -
Net debt -3.35800M -1.47300M -3.64400M -5.25300M -6.08700M
Short term debt 0.15M 0.33M 0.11M 0.12M 0.08M
Short long term debt - - - - -
Short long term debt total 0.18M 0.31M 0.39M 0.52M 0.60M
Other stockholder equity 88.06M 1.52M 18.31M 18.25M 18.34M
Property plant equipment - - - 0.82M 1.08M
Total current assets 6.23M 4.49M 6.29M 9.25M 10.36M
Long term investments - - - - -
Net tangible assets - - - 7.91M 8.51M
Short term investments - - - - -
Net receivables 2.70M 2.21M 0.94M 2.73M 3.12M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.07M 0.08M 0.09M 0.25M 0.73M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.36M 7.36M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00900M 0.04M - -
Deferred long term asset charges - - - - -
Non current assets total 7.61M 6.70M 6.70M 5.40M 3.79M
Capital lease obligations 0.18M 0.31M 0.39M 0.52M 0.60M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -0.37700M -1.86400M -2.23900M -2.15300M
Change to liabilities - - - -0.69600M -0.41000M
Total cashflows from investing activities -0.87000M -0.37700M - -2.23900M -2.15300M
Net borrowings - - - -0.11400M -0.04400M
Total cash from financing activities 3.50M -0.13400M -0.15600M -0.11400M 0.27M
Change to operating activities - - - - -
Net income -1.65100M -2.00100M -1.17800M 1.03M 1.57M
Change in cash 1.75M -2.24400M -1.73800M -0.91500M -1.26100M
Begin period cash flow 1.79M 4.03M 5.77M 6.68M 7.95M
End period cash flow 3.54M 1.79M 4.03M 5.77M 6.68M
Total cash from operating activities -0.88300M -1.73200M 0.30M 1.42M 0.61M
Issuance of capital stock 3.70M 0.00000M 0.00200M 0.00000M 0.31M
Depreciation 0.41M 0.47M 0.62M 0.64M 0.61M
Other cashflows from investing activities - -0.34300M - 0.00600M 0.00100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.26M -0.55900M - 0.28M -1.11200M
Sale purchase of stock - - - - 0.31M
Other cashflows from financing activities -0.19400M -0.13400M -0.15800M -0.11400M -0.04400M
Change to netincome - - - 0.17M -0.04900M
Capital expenditures 0.05M 0.47M 1.96M 2.25M 2.15M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.42M -0.20800M 0.96M -0.41600M -1.52200M
Stock based compensation 0.23M 0.00800M 0.05M 0.08M 0.20M
Other non cash items -0.28900M -0.00600M -0.43100M 0.09M -0.19200M
Free cash flow -0.93400M -2.20300M -1.66100M -0.82100M -1.54100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IXI
IXICO PLC		 - -% 8.65 - 47.39 1.05 0.62 0.60 5.66
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.

IXICO PLC

Griffin Court, London, United Kingdom, EC1A 9PN

Key Executives

Name Title Year Born
Mr. Giulio Cerroni CEO & Director 1962
Mr. Grant Nash CFO, Company Sec. & Exec. Director NA
Prof. Daniel Rueckert Co-Founder & Member of Scientific Advisory Board NA
Prof. Derek Lionel Glendon Hill Co-Founder and Pres of Regulatory Science & External Relations 1966
Prof. David Hawkes Co-Founder & Member of Scientific Advisory Board NA
Prof. Joseph Hajnal Co-Founder & Member of Scientific Advisory Board NA
Mr. Marcus Thornton Chief Operating Officer NA
Mr. Mark Austin Director of Technology NA
Dr. Robin Wolz Chief Scientific Officer NA
Ms. Hannah Esfahanian HR Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions